Hematologic Neoplasms: Clinical Trials

35 trials for Hematologic Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 7 not yet recruiting, 7 unknown, 6 recruiting. 35 Early Phase 1.

By phase and status

PhaseTrialsStatus
Early Phase 135Completed 8, Not yet recruiting 7, Unknown 7, Recruiting 6, Terminated 4, Withdrawn 2, Active not recruiting 1

Follow Hematologic Neoplasms: new trials by email Literature Review of Hematologic Neoplasms trials Research Report on Hematologic Neoplasms

Trials (filtered) newest first · largest first

All 35 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Dose-Escalation/Expansion Study of iMagic in Relapsed/Refractory Hematologic Malignancies
iMagic Injection (IMV101), iMagic Injection (IMV102) - Relapsed/Refractory Hematologic Malignancies
Early Phase 1Not yet recruitingSuzhou Immunofoco Biotechnology Co., Ltd302026-12-102026-11-04
Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation
Venetoclax, Hematopoietic Cell Transplantation Conditioning Regimen, Kidney Transplant - Kidney Failure Chronic, Stem Cell Transplant
Early Phase 1RecruitingMassachusetts General Hospital32026-02-042026-10-14
Exploratory Study on the Treatment of Recurrent and Refractory Hematological Malignancies With WGb-0302 Injection
WGb-0302 injection - Hematological Malignancies
Early Phase 1Not yet recruitingSichuan University202026-02-012026-01-23
Exploratory Study on in Vivo CAR-T Therapy Targeting CD20 for the Treatment of Hematological Malignancies
In vivo CAR-T drug targeting CD20 based on mRNA-LNP - Hematological Malignancies
Early Phase 1Not yet recruitingThe 923rd Hospital of Joint Logistics Support Force of People's Liberation Army472026-01-262026-01-23
HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT
Abatacept - Hematologic Malignancy
Early Phase 1RecruitingDuke University102025-11-122026-11-06
A Clinical Study to Evaluate the Safety and Efficacy of Anti-human CD 7 CAR-NK Cell Injection in Subjects With Relapsed and Refractory CD7-positive Hematological Malignancy
Anti-human CD7 CAR-NK cell injection - Immunology, Hematologic Malignancies
Early Phase 1Not yet recruitingShanghai General Hospital, Shanghai Jiao Tong University School of Medicine182025-09-012025-08-12
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in Adult Participants With Relapsed/Refractory CD19-positive B-cell Malignant Hematological Tumors
GT719 Injection - Hematological Malignancy (Leukemia- Lymphoma)
Early Phase 1RecruitingGrit Biotechnology342025-03-102025-12-30
Early Clinical Study of JY306 Universal NK Cell Injection in the Treatment of Adult Relapsed or Refractory CD70+ Malignant Hematologic Tumors
JY306 universal NK cell injection - Relapsed or Refractory Hematological Malignancies
Early Phase 1Not yet recruitingThe First Affiliated Hospital with Nanjing Medical University182025-02-152025-02-20
CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial
Autologous CAR123 T lymphocytes - Leukemia, Myeloid, Acute(AML), Precursor Cell Lymphoblastic Leukemia-Lymphoma
Early Phase 1Active not recruitingInstitute of Hematology and Blood Transfusion, Czech Republic182024-10-232026-09-14
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Darzalex Faspro (Daratumumab and hyaluronidase-fihj), JH-DSA Semi-Quant Screen and Response Score - Hematologic Malignancy, Bone Marrow Transplant Rejection
Early Phase 1RecruitingSidney Kimmel Comprehensive Cancer Center at Johns Hopkins82024-09-192026-10-05
Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion
Alteplase, Placebo Administration - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Early Phase 1RecruitingM.D. Anderson Cancer Center302023-08-172026-08-17
RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies
RD13-02 cell infusion - Hematologic Malignancies
Early Phase 1CompletedHenan Cancer Hospital62023-06-262024-11-22
RD13-02 CAR-T Cell Injection for Patients With r/r CD7+ T-ALL/T-LBL
RD13-02 cell infusion - Neoplasms, Hematologic Neoplasms
Early Phase 1CompletedXiaoyu Zhu42023-04-302024-11-21
Research Development13(RD13)-02 Cell Injection in Patients With Relapsed or Refractory Cluster Of Differentiation 7(CD7)-Positive Hematological Malignancies
RD13-02 cell infusion - Neoplasms, Hematologic Neoplasms
Early Phase 1CompletedMEI HENG22023-03-102026-02-03
Research Development(RD)13-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7(CD7)+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML)
RD13-02 cell infusion - Neoplasms, Hematologic Neoplasms
Early Phase 1CompletedKai Lin Xu,MD82023-03-082024-11-21
CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBL
RD13-02 cell infusion - Neoplasms, Hematologic Neoplasms
Early Phase 1CompletedHe Huang202023-02-092024-11-21
Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignancies
engineered red blood cell - Cancer, Solid Tumor
Early Phase 1UnknownWestlake Therapeutics302023-01-162024-07-24
A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients (SuppCare 001)
isatuximab 10 mg/kg - Platelet Refractoriness, Hematologic Malignancy
Early Phase 1TerminatedFiras El Chaer, MD32022-11-292024-07-31
Thermal Therapy for the Treatment of Depression in Cancer Survivors, the S-WARM Study
Quality-of-Life Assessment, Questionnaire Administration, Thermotherapy - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Early Phase 1WithdrawnRoswell Park Cancer Institute2021-05-062022-05-12
Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies
CT125A cells, Cyclophosphamide, fludarabine - CD5+ Relapsed/Refractory Hematopoietic Malignancies, Chronic Lymphocytic Leukemia (CLL)
Early Phase 1UnknownHuazhong University of Science and Technology182021-03-012021-02-23

Showing 20 of 35. Sign in to see all of them.

Narrower conditions

Myelodysplastic Syndromes (6)  ·  Neoplasms (6)  ·  Leukemia, Myeloid, Acute (5)  ·  Hematologic Diseases (4)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (4)  ·  Leukemia (3)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (3)  ·  Lymphoma, Follicular (3)  ·  Lymphoma, Large B-Cell, Diffuse (3)  ·  Lymphoma, Mantle-Cell (3)  ·  Lymphoma, Non-Hodgkin (3)  ·  Multiple Myeloma (3)  ·  Myeloproliferative Disorders (3)  ·  Polycythemia Vera (3)

Broader conditions

Hemic and Lymphatic Diseases (35)  ·  Neoplasms by Site (33)  ·  Hematologic Diseases (31)  ·  Neoplasms (29)  ·  Pathologic Processes (11)  ·  Pathological Conditions, Signs and Symptoms (11)  ·  Disease Attributes (9)  ·  Bone Marrow Diseases (8)  ·  Neoplasms by Histologic Type (8)  ·  Chronic Disease (6)  ·  Immune System Diseases (6)  ·  Immunoproliferative Disorders (6)  ·  Lymphatic Diseases (6)  ·  Leukemia, Lymphoid (5)  ·  Leukemia, Myeloid (5)

Interventions

Abatacept (1)  ·  Biopsy (1)  ·  CF regimen (1)  ·  Cell- and Tissue-Based Therapy (1)  ·  Continuous Positive Airway Pressure (1)  ·  Counseling (1)  ·  Diathermy (1)  ·  Hydrocodone (1)  ·  Hydromorphone (1)  ·  Hyperthermia, Induced (1)  ·  Kidney Transplantation (1)  ·  Levorphanol (1)  ·  Lisaftoclax (1)  ·  Morphine (1)  ·  Observation (1)

Sponsors

M.D. Anderson Cancer Center (4)  ·  Northwestern University (2)  ·  Zhejiang University (2)  ·  iCell Gene Therapeutics (2)  ·  Ascentage Pharma Group Inc. (1)  ·  Duke University (1)  ·  Firas El Chaer, MD (1)  ·  Grit Biotechnology (1)  ·  He Huang (1)  ·  Henan Cancer Hospital (1)  ·  Huazhong University of Science and Technology (1)  ·  Institute of Hematology and Blood Transfusion, Czech Republic (1)  ·  Kai Lin Xu,MD (1)  ·  MEI HENG (1)  ·  Massachusetts General Hospital (1)

Countries

China (15)  ·  United States (14)  ·  Australia (1)  ·  Czechia (1)

Top investigators

Fang Liu, MD, PhD (2)  ·  Hongyu Zhang, MD, PhD (2)  ·  Akhila S Reddy (1)  ·  Anurag K Singh (1)  ·  Brady Stein, MD (1)  ·  Christian B Gocke, MD, PhD (1)  ·  David Marin, MD (1)  ·  Firas El Chaer, MD (1)  ·  Gerardo Colon-Otero, M.D. (1)  ·  Horiana Grosu, M D (1)  ·  Jan Vydra, MD, PhD (1)  ·  Jeffrey J. Raizer, MD (1)  ·  Jianfeng Zhou, PhD, MD (1)  ·  Krishna Sundar (1)  ·  Partow Kebriaei, MD (1)

Results publications

PMID 38143760, PMID 41633358

NIH funding

P01CA148600 (1), P30CA015083 (1), P30CA042014 (1), P30CA060553 (1), P30CA072720 (1)